newsfilter
← Latest News
Business Wire·

Axcella Granted Patent for Long COVID Fatigue Treatment

Claims cover methods of treating a subject presenting with fatigue from post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, with Candidate AXA1125 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage